Head Injuries, Penetrating

Temporary vessel occlusion a growing practice for trauma patients. SALT LAKE CITY, June 13, 2024 /PRNewswire/ -- Emergency Scientific, a Utah-based medical device company specializing in innovative solutions for the emergency medicine industry, has announced the first patient use of its Landmark REBOA Catheter. The Landmark Catheter was developed for resuscitative endovascular occlusion of the aorta (REBOA), a procedure developed by the military to treat hemorrhage from non-compressible fractures of the pelvis and penetrating trauma of the abdomen and has since been adopted by civilian providers. REBOA is also used for postpartum hemorrhage (PPH), cardiac arrest (CA), abdominal aortic aneurysm (AAA) ruptures, and gastrointestinal (GI) bleeds. "Landmark was easy to use and easy to deliver with a smooth insertion," said Scott T. Youngquist, MD, MS, FACEP, FAEMS, FAHA, an emergency medicine physician at the University of Utah who performed the first case. "REBOA can be an important tool to aid in patient resuscitation." It is estimated that more than 60,000 people die every year in the United States from traumatic hemorrhage, making it the number one cause of death in patients under 45 years old.1,2 "We are pleased to offer another solution for physicians to treat challenging emergency hemorrhage," said Ryan Murri, Emergency Scientific's Chief Executive Officer. "With high quality emergency medicine solutions, we hope to be able to save more patients suffering life threatening injuries. We believe nobody should die from the loss of blood who could be saved with the right tools, and we look forward to continuing to serve our healthcare partners with additional novel treatment options." The Landmark REBOA Catheter recently received FDA 510(k) clearance and is indicated for temporary occlusion of large vessels including patients requiring emergency control of hemorrhage. Emergency Scientific is a privately held company engaged in the development, manufacturing, and distribution of novel emergency medicine solutions. Latif, R.K., Clifford, S.P., Baker, J.A. et al. Traumatic hemorrhage and chain of survival. Scand J Trauma Resusc Emerg Med 31, 25 (2023). Kauvar, David S. MD; Lefering, Rolf PhD; Wade, Charles E. PhD. Impact of Hemorrhage on Trauma Outcome: An Overview of Epidemiology, Clinical Presentations, and Therapeutic Considerations. The Journal of Trauma: Injury, Infection, and Critical Care 60(6):p S3-S11, June 2006. SOURCE Emergency Scientific

New film starring Jennifer Lawrence depicts experience of U.S. Veteran with traumatic brain injury with scientific accuracy and depiction of invisible wounds NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Cohen Veterans Bioscience (CVB) fully supports portrayals in Causeway for its accurate depiction of traumatic brain injury and the Veteran experience. Cohen Veterans Bioscience is pleased to see brave artists take an unflinching approach to bring this difficult topic of TBI out of the shadows. Jennifer Lawrence stars as a military engineer healing from TBI and the invisible wounds of war. The film follows "Lynsey," who suffers a traumatic brain injury while deployed in Afghanistan and her struggles with rehabilitation and depression adjusting to life back home. "We hope the film Causeway will do for traumatic brain injuries (TBI) what Concussion did for CTE in taking the first step of normalizing the conversation by spreading awareness about these invisible wounds. CVB is committed to advancing the science of and treatments for TBI and we encourage all people touched by traumatic brain injury to openly discuss and seek the help they need to heal," said Magali Haas, MD, PhD, CEO & President, Cohen Veterans Bioscience. What Is Traumatic Brain Injury (TBI)? TBIs result from a bump, blow, or jolt to the head, or from a penetrating head injury. Explosive blasts can also cause TBIs; this is a particular concern among those who serve in the military. Essentially, any external force that causes the brain to move within the head can disrupt normal brain function, leading to loss of consciousness, or being dazed and confused. Clinical Signs of Alteration in Brain Function Any period of loss of or decreased consciousness Any loss of memory for events immediately before or after the injury Neurologic deficits such as muscle weakness, loss of balance and coordination, disruption of vision, change in speech and language, or sensory loss Any alteration in mental state at the time of the injury such as confusion, disorientation, slowed thinking, or difficulty with concentration TBI in Veterans: a Population of Special Concern Military service members and veterans of recent conflicts and combat are a population of special concern. Since September 11, 2001, the U.S. has deployed more than 2.7 million men and women to support combat operations in Iraq and Afghanistan. According to the Department of Defense's evaluation of U.S. military casualty statistics: From 2000-2019 Q3, 413,858 United States military personnel worldwide experienced a TBI; 82.8% were considered mild, 9.8% moderate, and 2.3% penetrating or severe. The incidence of TBI has increased since 2000, with a peak in 2011 and 2012. Approximately 80% of new TBI cases occur in non-deployed settings, with military members also sustaining TBIs during training activities. Out of 770,000 veterans of Operations Enduring Freedom and Iraqi Freedom who sought care from a VA Medical Center, nearly 60,000 were evaluated or treated for a TBI-related condition. Further, military personnel with a history of mild TBI are at an increased risk for developing post-traumatic stress (PTS). Among U.S. Army infantry soldiers returning from Iraq, 43.9% of those who reported a TBI with loss of consciousness also reported symptoms of PTS. About Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics. We are accelerating the development of next-generation diagnostics and treatments for brain disorders by harnessing the power of biotechnology (including neuroimaging, 'omics, and biosensors) in combination with high-performance computing and data analytics, to understand the underlying mechanisms of disease and discover new ways to improve brain health SOURCE Cohen Veterans Bioscience

Philanthropic Support and Continuous Supply of Hemostats Crucial amidst COVID-19 Pandemic Healthcare companies in the flowable hemostats market are increasing the supply of life-sustaining medicines and medical devices such as flowable hemostats amidst dire times of the coronavirus (COVID-19) pandemic. They are expanding job opportunities for individuals to help meet increased product demand. Increasing product supply chain is one of the key focus points for companies in the flowable hemostats market, since COVID-19 is challenging communities and healthcare systems around the world. Manufacturers are maximizing their production activities by making hemostats and other medical devices available round the clock. In-house medical teams of med-tech companies are actively working with governments, clinicians, and healthcare systems to understand unique challenges created by COVID-19. Leading med-tech companies are extending philanthropic support by providing financial support to frontline healthcare workers and communities. They are extending geographic-specific support in order to improve clinical outcomes. Request Brochure of Report - Fully Stocked Inventory Creates Consistency in Supply Chains for Surgeons Establishing a robust supply chain has helped med-tech companies in the flowable hemostats market to gain a competitive edge over other market players. As such, the market is highly consolidated with only three players accounting for a combined market share of ~97% during the forecast period. Hence, manufacturers are building their inventory to meet requirements in difficult-to-access bleeding situations. For instance, global leaders in consumer healthcare and medical devices are strengthening their supply for flowable hemostats by entering into strategic partnerships with distributors. Request for Analysis of COVID-19 Impact on Flowable Hemostats Market – Companies in the flowable hemostats market are developing devices that work fast and improve visibility. Fast mechanism of advanced flowable hemostats helps to stop difficult-to-access bleeding in less time. Thus, surgeons can count on a fully stocked inventory with a consistent supply of hemostats. Gelatin matrix hemostats are acquiring prominence in the market, as the total combined revenue of porcine and bovine gelatin materials is estimated to reach ~US$ 1 Bn by the end of 2027. High Demand for Flowable Hemostats in Partial Splenectomy after Penetrating Trauma Hemostatic agents are in high demand for prehospital hemorrhage control. As such, the revenue of general surgery applications is the highest in the flowable hemostats market. This has fueled the demand for thrombin-gelatin hemostatic matrix in devices, owing to its safety and efficacy profiles. For instance, Baxter International— a leading manufacturer of products for treatment of life-threatening conditions is gaining popularity for its FLOSEAL Hemostatic Matrix, which is better than microporous polysaccharide powder materials. Companies in the flowable hemostats market are increasing efforts to introduce special applicator syringe in devices. Thrombin-gelatin hemostatic matrix in flowable hemostats are being highly publicized in cardiovascular surgeries, hepatic surgeries, and endoscopic sinus surgeries. There is a growing demand for flowable hemostats that deploy effective hemostasis in partial splenectomy after penetrating trauma. Tranexamic acid-loaded starch microspheres hold promising potentials in hemostatic stability. Likewise, drug-loaded materials are projected to show better hemostatic performance in comparison with commercial hemostat made of microporous polysaccharide hemispheres. Buy Flowable Hemostats Market Report at